Search

Displaying results 8521 - 8530 of 10000 in total
  1. Drug

    Fibroblast growth factor-1

    go.drugbank.com/drugs/DB05599
    Investigational

  2. Drug

    CTCE-9908

    go.drugbank.com/drugs/DB05625
    Investigational

  3. Drug

    Pemoline

    go.drugbank.com/drugs/DB01230
    ApprovedIllicitWithdrawn

    In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.

  4. Drug

    Methapyrilene

    go.drugbank.com/drugs/DB04819
    ApprovedWithdrawn

    Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.

  5. Drug

    Nesvategrast

    go.drugbank.com/drugs/DB19337
    Investigational

    Nesvategrast is under investigation in clinical trial NCT05409235 (Nesvategrast (OTT166) in Diabetic Retinopathy (DR)).

  6. Drug

    Inlexisertib

    go.drugbank.com/drugs/DB21713
    Investigational

    Inlexisertib is under investigation in clinical trial NCT05957367 (A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies). … Inlexisertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Inlexisertib is a serine/threonine kinase inhibitor.

  7. Drug

    UDP-alpha-D-glucuronic acid

    go.drugbank.com/drugs/DB03041
    Experimental

    It may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones.

  8. Drug

    Exicorilant

    go.drugbank.com/drugs/DB16162
    Investigational

    Exicorilant is under investigation in clinical trial NCT03437941 (Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With Mcrpc).

  9. Drug

    Surzebiclimab

    go.drugbank.com/drugs/DB16669
    Investigational

    Surzebiclimab is under investigation in clinical trial NCT03744468 (Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors).

  10. Drug

    Atamparib

    go.drugbank.com/drugs/DB19028
    Investigational

    Atamparib is under investigation in clinical trial NCT05127590 (RBN-2397 in Combination With Pembrolizumab in Patients With SCCL).